T-Cell Engagers — Modern Immune-Based Therapies for Multiple Myeloma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
T-Cell Engagers — Modern Immune-Based Therapies for Multiple Myeloma
Authors
Keywords
-
Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume 387, Issue 6, Pages 558-561
Publisher
Massachusetts Medical Society
Online
2022-08-11
DOI
10.1056/nejme2209692
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis
- (2022) Kerstin N Vokinger et al. LANCET ONCOLOGY
- Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
- (2022) Thomas Martin et al. JOURNAL OF CLINICAL ONCOLOGY
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study
- (2021) Sagar Lonial et al. CANCER
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
- (2021) Jesus G Berdeja et al. LANCET
- Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study
- (2021) Suzanne Trudel et al. BLOOD
- A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
- (2021) Shaji Kumar et al. BLOOD
- Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma
- (2021) Sham Mailankody et al. BLOOD
- First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial
- (2020) Luciano J. Costa et al. BLOOD
- Emerging immunotherapies in multiple myeloma
- (2020) Urvi A Shah et al. BMJ-British Medical Journal
- Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
- (2020) Shaji K Kumar et al. LANCET ONCOLOGY
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
- (2019) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- Immunotherapy Combinations in Multiple Myeloma — Known Unknowns
- (2018) Nicole J. Gormley et al. NEW ENGLAND JOURNAL OF MEDICINE
- The high price of anticancer drugs: origins, implications, barriers, solutions
- (2017) Vinay Prasad et al. Nature Reviews Clinical Oncology
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
- (2016) S. A. Ali et al. BLOOD
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started